# Iwona Ługowska

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/iwona-ugowska/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,114 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 32 |
| i10-index | 75 |
| Last Known Institution | National Institute of Oncology |
| OpenAlex ID | https://openalex.org/A5041689810 |
| ORCID iD | 0000-0001-9511-178X |
| Works | 249 |

## Researcher papers

- [Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for/)
- [Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial](https://scholariq.org/papers/efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice-guidelines-for/)
- [Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/bone-sarcomas-esmo-paedcan-euracan-clinical-practice-guidelines-for-diagnosis/)
- [Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial](https://scholariq.org/papers/histotype-tailored-neoadjuvant-chemotherapy-versus-standard-chemotherapy-in/)
- [Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups](https://scholariq.org/papers/neoadjuvant-chemotherapy-in-high-risk-soft-tissue-sarcomas-final-results-of-a/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)
- [Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”](https://scholariq.org/papers/corrections-to-soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice/)
- [Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”](https://scholariq.org/papers/corrections-to-gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice/)
- [Immunotherapy of melanoma](https://scholariq.org/papers/immunotherapy-of-melanoma/)
- [Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer](https://scholariq.org/papers/patient-experience-of-medication-administration-and-development-of-a-patient/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [National Institute of Oncology](https://scholariq.org/institutions/national-institute-of-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.